Science Corporation closes $230M Series C at $1.5B valuation to commercialize grain-of-rice retinal implant
Summary
Science Corporation raised $230M Series C led by Khosla Ventures at a $1.5B valuation to commercialize PRIMA — a retinal implant smaller than a grain of rice for advanced macular degeneration. CE mark application submitted to EU; approval expected mid-2026 with Germany as first market. This would make Science Corp the first BCI company with a commercially available product globally, ahead of Neuralink and Synchron.
Why it matters
A $1.5B valuation for a pre-revenue BCI company backed by Khosla reflects the extraordinary commercial conviction in PRIMA. Science Corp is racing to claim the milestone of being first-to-market with a commercially cleared BCI — a title worth immense strategic value in the race for regulatory, investor, and clinical credibility.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial